Methamphetamine Use and Cardiovascular Disease

Kevil, Christopher G.; Goeders, Nicholas E.; Woolard, Matthew D.; Bhuiyan, Md. Shenuarin; Dominic, Paari; Kolluru, Gopi K.; Arnold, Connie L.; Traylor, James; Orr, A. Wayne

doi:10.1161/atvbaha.119.312461

Cited by 183 publications

(173 citation statements)

References 63 publications

Supporting

Mentioning

146

Contrasting

Unclassified

Order By: Relevance

“…The long‐term health effects of MA use include cognitive impairments, anxiety, insomnia, and cardiovascular disease (Darke, Duflou, & Kaye, 2017; Huckans, Fuller, Chalker, Adams, & Loftis, 2015; Kevil et al., 2019; Prakash et al., 2017). Aside from the neurotoxic effects and overdose, cardiovascular disease is the leading cause of death for MA users (Darke et al., 2017; Kevil et al., 2019). Compulsive drug use and craving are hallmark behaviours of addiction that are attributed to maladaptive changes in plasticity of dopamine (DA) neurons (Kauer & Malenka, 2007; Koob & Bloom, 1988).…”

Section: Introductionmentioning

confidence: 99%

Methamphetamine use alters human plasma extracellular vesicles and their microRNA cargo: An exploratory study

Sandau

Duggan

Shi

et al. 2020

J of Extracellular Vesicle

View full text Add to dashboard Cite

Methamphetamine (MA) is the largest drug threat across the globe, with health effects including neurotoxicity and cardiovascular disease. Recent studies have begun to link microRNAs (miRNAs) to the processes related to MA use and addiction. Our studies are the first to analyse plasma EVs and their miRNA cargo in humans actively using MA (MA‐ACT) and control participants (CTL). In this cohort we also assessed the effects of tobacco use on plasma EVs. We used vesicle flow cytometry to show that the MA‐ACT group had an increased abundance of EV tetraspanin markers (CD9, CD63, CD81), but not pro‐coagulant, platelet‐, and red blood cell‐derived EVs. We also found that of the 169 plasma EV miRNAs, eight were of interest in MA‐ACT based on multiple statistical criteria. In smokers, we identified 15 miRNAs of interest, two that overlapped with the eight MA‐ACT miRNAs. Three of the MA‐ACT miRNAs significantly correlated with clinical features of MA use and target prediction with these miRNAs identified pathways implicated in MA use, including cardiovascular disease and neuroinflammation. Together our findings indicate that MA use regulates EVs and their miRNA cargo, and support that further studies are warranted to investigate their mechanistic role in addiction, recovery, and recidivism.

show abstract

Section: Introductionmentioning

confidence: 99%

Methamphetamine use alters human plasma extracellular vesicles and their microRNA cargo: An exploratory study

Sandau

Duggan

Shi

et al. 2020

J of Extracellular Vesicle

View full text Add to dashboard Cite

show abstract

“…ethamphetamine (METH) is a highly addictive amphetamine class psychostimulant drug whose illicit use is dramatically increasing in the United States 1,2 . It has been reported that~1.6 million Americans used METH in 2017, with 964,000 cases (up from 684,000 cases in 2016) of emergency room visits owing to METH abuse associated disorders [3][4][5] .…”

mentioning

confidence: 99%

“…METH is toxic to both neuronal and cardiovascular systems; cardiovascular disease is the second leading cause of death among METH abusers following accidental overdose 6,7 . METH abuse associated with cardiovascular toxicity includes hypertension, tachycardia, cardiac arrhythmia, acute coronary vasospasm, myocardial infarction, and cardiomyopathy 1,2,[6][7][8] . Clinical case studies of the hearts of human METH users have revealed severely reduced left ventricular (LV) ejection fraction, LV chamber dilatation, myocardial lesions, cardiac hypertrophy, fibrosis, and inflammation in relatively younger patients (≤50 years) with no other significant cardiac risk factors 6,[9][10][11] .…”

mentioning

confidence: 99%

Methamphetamine induces cardiomyopathy by Sigmar1 inhibition-dependent impairment of mitochondrial dynamics and function

et al. 2020

Self Cite

View full text Add to dashboard Cite

Methamphetamine-associated cardiomyopathy is the leading cause of death linked with illicit drug use. Here we show that Sigmar1 is a therapeutic target for methamphetamine-associated cardiomyopathy and defined the molecular mechanisms using autopsy samples of human hearts, and a mouse model of “binge and crash” methamphetamine administration. Sigmar1 expression is significantly decreased in the hearts of human methamphetamine users and those of “binge and crash” methamphetamine-treated mice. The hearts of methamphetamine users also show signs of cardiomyopathy, including cellular injury, fibrosis, and enlargement of the heart. In addition, mice expose to “binge and crash” methamphetamine develop cardiac hypertrophy, fibrotic remodeling, and mitochondrial dysfunction leading to contractile dysfunction. Methamphetamine treatment inhibits Sigmar1, resulting in inactivation of the cAMP response element-binding protein (CREB), decreased expression of mitochondrial fission 1 protein (FIS1), and ultimately alteration of mitochondrial dynamics and function. Therefore, Sigmar1 is a viable therapeutic agent for protection against methamphetamine-associated cardiomyopathy.

show abstract

“…A high proportion of participants across all professional groups selected substance abuse as a risk factor for CVD (overall 81% of the whole sample). Studies from the general population have shown recreational drugs such as methamphetamine and cocaine can provoke a multifactorial dysfunction of the cardiovascular system [42,43]. Prevalence of substance abuse is high in people with schizophrenia [44], whereby between 40 and 50% of people with schizophrenia may have a comorbid substance use disorder (SUD) [45].…”

Section: Discussionmentioning

confidence: 99%

Examining healthcare professionals’ beliefs and actions regarding the physical health of people with schizophrenia

Berry

Drake

Yung

2020

BMC Health Serv Res

View full text Add to dashboard Cite

Background: People with schizophrenia have a higher premature mortality risk compared with the general population mainly due to cardiovascular disease (CVD). Despite this, people with schizophrenia are less likely to access physical health services or have their physical health investigated and monitored. Aims: To examine the beliefs and actions of mental health professionals regarding the physical health of people with schizophrenia. Method: Two hundred and fifty-five healthcare professionals who support people with schizophrenia within Greater Manchester Mental Health NHS Foundation Trust (GMMH), United Kingdom and Pennine Care NHS Foundation Trust (PCFT), United Kingdom took part. Beliefs and actions were assessed using a self-administered questionnaire, which was constructed around two primary domains (1) CVD risk factors; and (2) physical health interventions. Descriptive statistics were reported and responses between different healthcare professional groups were compared. Results: The overwhelming majority of participants were aware of established CVD risk factors with 98% identifying family history of CVD, 98% for smoking and 96% for high blood pressure. Most participants believed nearly all healthcare professionals were responsible for monitoring the physical health of people with schizophrenia, regardless of job speciality. There were 67% of participants who reported delivering an intervention to improve sedentary behaviour for people with schizophrenia. However, awareness of government and NHS recommended lifestyle interventions were low. Conclusions: This study found good knowledge regarding many established CVD risk factors but little clarity regarding who is responsible for monitoring the physical health of people with schizophrenia and how often brief lifestyle interventions are being implemented.

show abstract

Methamphetamine Use and Cardiovascular Disease

Cited by 183 publications

References 63 publications

Methamphetamine use alters human plasma extracellular vesicles and their microRNA cargo: An exploratory study

Methamphetamine use alters human plasma extracellular vesicles and their microRNA cargo: An exploratory study

Methamphetamine induces cardiomyopathy by Sigmar1 inhibition-dependent impairment of mitochondrial dynamics and function

Examining healthcare professionals’ beliefs and actions regarding the physical health of people with schizophrenia

Contact Info

Product

Resources

About